Heliyon, Journal Year: 2024, Volume and Issue: 10(21), P. e39996 - e39996
Published: Nov. 1, 2024
Language: Английский
Antioxidants, Journal Year: 2024, Volume and Issue: 13(6), P. 671 - 671
Published: May 30, 2024
Carfilzomib is an irreversible proteasome inhibitor used for multiple myeloma patients. However, carfilzomib treatment associated with cardiovascular complications. Empagliflozin, Sodium Glucose Co-transporter 2 (SGLT-2) inhibitor, oral antidiabetic drug proven antioxidant and anti-inflammatory properties. The aim of the present study was to determine cardioprotective effects empagliflozin against carfilzomib-induced cardiotoxicity. C57BL/6 mice were randomly divided into four groups: control, empagliflozin, carfilzomib, + empagliflozin. Empagliflozin prevented cardiotoxicity by ameliorating histological alterations, CK-MB, troponin-I. Moreover, it inhibited oxidative damage inflammation via its action on catalase activity, reduced glutathione levels superoxide dismutase nuclear factor-κB (p65) cytokine levels. Mechanistically, abrogated endoplasmic reticulum stress induced as evidenced effect Regulated Protein-78 (GRP-78)/Activating Transcription Factor 6 (ATF6)/C/EBP homologous protein (CHOP) axis. Intriguingly, significantly autophagy, that further enhanced increased LC3B beclin-1 mRNA expression p62 expression. apoptosis confirmed active caspase-3. Importantly, did not alter cytotoxic human U266B1 cells. our findings suggest may provide a new therapeutic strategy mitigate in
Language: Английский
Citations
6
Molecular and Cellular Biochemistry, Journal Year: 2024, Volume and Issue: unknown
Published: Aug. 19, 2024
Language: Английский
Citations
6
Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(1), P. 134 - 134
Published: Jan. 20, 2025
Diabetes mellitus (DM) is a multifaceted disorder with pandemic spread and remarkable burden of cardiovascular mortality morbidity. Diabetic cardiomyopathy (DBCM) has been increasingly recognized as the development cardiac dysfunction, which accompanied by heart failure (HF) symptoms in absence obvious reasons like ischemic disease, hypertension, or valvulopathies. Several pathophysiological mechanisms have proposed, including metabolic disorders (e.g., glycation products), oxidative stress, low-grade inflammation, mitochondrial etc., should guide new therapeutic strategies. Up to now, HF treatment not differed between patients without diabetes, limits expected benefits despite high risk former group. However, DBCM may require different management, prioritize anti-diabetic medications testing other novel therapies. This review aims appraise challenges prospectives individualized pharmaceutical therapy for DBCM.
Language: Английский
Citations
0
Cardiovascular Drugs and Therapy, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 6, 2025
Language: Английский
Citations
0
Biomedicine & Pharmacotherapy, Journal Year: 2025, Volume and Issue: 184, P. 117924 - 117924
Published: Feb. 20, 2025
Language: Английский
Citations
0
Cardiovascular Diabetology, Journal Year: 2025, Volume and Issue: 24(1)
Published: April 28, 2025
As a heterogeneous syndrome, heart failure with preserved ejection fraction (HFpEF) has become the leading form of worldwide. Increasing evidence identified that diabetes mellitus (DM) increases risk HFpEF. Worse still, coexistence both diseases poses great threat to human health by further worsening cardiovascular system and accelerating progression diabetes. Although several studies have indicated novel antidiabetic drugs, including sodium glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RA) dipeptidyl peptidase 4 (DPP4i) provide benefits in T2DM patients HFpEF, elaborated roles mechanisms are not fully understood. In this review, we summarize state-of-the-art regarding epidemiology pathophysiology diabetic landscape drugs treatment as well discuss relevant mechanisms, aiming broaden understanding HFpEF gain new insight into disease.
Language: Английский
Citations
0
International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(14), P. 7711 - 7711
Published: July 14, 2024
Sodium–glucose cotransporter 2 inhibitors (SGLT2i), a novel class of glucose-lowering drugs, have revolutionized the management heart failure with reduced and preserved ejection fraction, regardless presence diabetes, are currently incorporated in guidelines. While these drugs consistently demonstrated their ability to decrease hospitalizations several landmark clinical trials, cardioprotective effects far from having been completely elucidated. In past decade, growing body experimental research has sought address molecular cellular mechanisms SGLT2i order provide better understanding off-target acute chronic cardiac benefits, beyond on-target renal effect responsible for blood glucose reduction. The present narrative review addresses direct SGLT2i, delving into approved therapy, provides insights future perspectives.
Language: Английский
Citations
2
World Journal of Diabetes, Journal Year: 2024, Volume and Issue: 15(2), P. 137 - 141
Published: Feb. 4, 2024
Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as a pivotal intervention in diabetes management, offering significant cardiovascular benefits. Empagliflozin, particular, has demonstrated cardioprotective effects beyond its glucose-lowering action, reducing heart failure hospitalizations and improving cardiac function. Of note, the mechanisms appear to be inde-pendent of glucose lowering, possibly mediated through several involving shifts metabolism anti-fibrotic, anti-inflammatory, anti-oxidative pathways. This editorial summarizes multifaceted advantages SGLT2 inhibitors, highlighting need for further research elucidate their full therapeutic potential care.
Language: Английский
Citations
0
Heliyon, Journal Year: 2024, Volume and Issue: 10(21), P. e39996 - e39996
Published: Nov. 1, 2024
Language: Английский
Citations
0